| Brandi Watts Benson, AA-C | |
|
809 82nd Pkwy, Myrtle Beach, SC 29572-4607 | |
| (843) 692-1062 | |
| Not Available |
| Full Name | Brandi Watts Benson |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology Assistant |
| Experience | 15 Years |
| Location | 809 82nd Pkwy, Myrtle Beach, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538493267 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | 005698 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atlantic Coast Anesthesia Services Pc | 3971887167 | 90 |
| Beach Anesthesia, Llc | 6103924014 | 81 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.
Ian Humphreys, Sonal Saraiya, Walter Belenky and James Dworkin, at Detroit Medical Centre in Michigan proceeded to treat a four year old girl who had a rare hereditary disorder that brings prolonged bleeding, publishing their findings in the Annals of Otology, Rhinology and Laryngology.
A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.
White blood cell (WBC) count may predict cardiovascular events and risk of death in postmenopausal women who are not currently identified by traditional cardiovascular risk factors, according to an article in the March 14 issue of Archives of Internal Medicine.
Google is providing UNICEF with a $1 million grant to support the charity's efforts to combat the Zika virus.
› Verified 8 days ago
| Entity Name | Coastal Anesthesia Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609813179 PECOS PAC ID: 1850295650 Enrollment ID: O20031124000145 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.
Ian Humphreys, Sonal Saraiya, Walter Belenky and James Dworkin, at Detroit Medical Centre in Michigan proceeded to treat a four year old girl who had a rare hereditary disorder that brings prolonged bleeding, publishing their findings in the Annals of Otology, Rhinology and Laryngology.
A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.
White blood cell (WBC) count may predict cardiovascular events and risk of death in postmenopausal women who are not currently identified by traditional cardiovascular risk factors, according to an article in the March 14 issue of Archives of Internal Medicine.
Google is providing UNICEF with a $1 million grant to support the charity's efforts to combat the Zika virus.
› Verified 8 days ago
| Entity Name | Beach Anesthesia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215061429 PECOS PAC ID: 6103924014 Enrollment ID: O20070530000620 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.
Ian Humphreys, Sonal Saraiya, Walter Belenky and James Dworkin, at Detroit Medical Centre in Michigan proceeded to treat a four year old girl who had a rare hereditary disorder that brings prolonged bleeding, publishing their findings in the Annals of Otology, Rhinology and Laryngology.
A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.
White blood cell (WBC) count may predict cardiovascular events and risk of death in postmenopausal women who are not currently identified by traditional cardiovascular risk factors, according to an article in the March 14 issue of Archives of Internal Medicine.
Google is providing UNICEF with a $1 million grant to support the charity's efforts to combat the Zika virus.
› Verified 8 days ago
| Entity Name | Atlantic Coast Anesthesia Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932641313 PECOS PAC ID: 3971887167 Enrollment ID: O20170308000291 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.
Ian Humphreys, Sonal Saraiya, Walter Belenky and James Dworkin, at Detroit Medical Centre in Michigan proceeded to treat a four year old girl who had a rare hereditary disorder that brings prolonged bleeding, publishing their findings in the Annals of Otology, Rhinology and Laryngology.
A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.
White blood cell (WBC) count may predict cardiovascular events and risk of death in postmenopausal women who are not currently identified by traditional cardiovascular risk factors, according to an article in the March 14 issue of Archives of Internal Medicine.
Google is providing UNICEF with a $1 million grant to support the charity's efforts to combat the Zika virus.
› Verified 8 days ago
| Entity Name | Anesthesia Sc Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295271948 PECOS PAC ID: 6800172453 Enrollment ID: O20170413000961 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.
Ian Humphreys, Sonal Saraiya, Walter Belenky and James Dworkin, at Detroit Medical Centre in Michigan proceeded to treat a four year old girl who had a rare hereditary disorder that brings prolonged bleeding, publishing their findings in the Annals of Otology, Rhinology and Laryngology.
A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.
White blood cell (WBC) count may predict cardiovascular events and risk of death in postmenopausal women who are not currently identified by traditional cardiovascular risk factors, according to an article in the March 14 issue of Archives of Internal Medicine.
Google is providing UNICEF with a $1 million grant to support the charity's efforts to combat the Zika virus.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brandi Watts Benson, AA-C 134 Northgate Rd, Myrtle Beach, SC 29572-5618 Ph: () - | Brandi Watts Benson, AA-C 809 82nd Pkwy, Myrtle Beach, SC 29572-4607 Ph: (843) 692-1062 |
News Archive
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.
Ian Humphreys, Sonal Saraiya, Walter Belenky and James Dworkin, at Detroit Medical Centre in Michigan proceeded to treat a four year old girl who had a rare hereditary disorder that brings prolonged bleeding, publishing their findings in the Annals of Otology, Rhinology and Laryngology.
A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.
White blood cell (WBC) count may predict cardiovascular events and risk of death in postmenopausal women who are not currently identified by traditional cardiovascular risk factors, according to an article in the March 14 issue of Archives of Internal Medicine.
Google is providing UNICEF with a $1 million grant to support the charity's efforts to combat the Zika virus.
› Verified 8 days ago
Nyein Wint Mullenniex, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 134 N Gate Rd, Myrtle Beach, SC 29572 Phone: 843-272-7232 | |
Mr. Robert Edwin Jones Iv, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-692-1000 | |
Mrs. Natalie Anderson Kahn, AA-C Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-692-1000 | |
Dennis Haugen, AA-C Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-692-1062 | |
Ms. Nyree M Penn, AA-C Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 809 82nd Pkwy, Grand Strand Regional Medical Center, Myrtle Beach, SC 29572 Phone: 843-692-1000 | |
Kathleen Starrs, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-692-1000 | |
Kassandra Jean Carpenter, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-692-1062 |